Determination of alentamol hydrobromide, a novel antipsychotic agent, in human blood plasma and urine by high-performance liquid chromatography with fluorescence detection and solid-phase extraction

Alentamol hydrobromide, (+)-2-(dipropylamino)-2,3-dihydro-1H-phenalen-5-ol monohydrobromide, is a selective dopamine agonist currently being investigated for the treatment of schizophrenia. This paper describes a reversed-phase high-performance liquid chromatographic-based method for the quantificat...

Full description

Saved in:
Bibliographic Details
Published inJournal of chromatography Vol. 565; no. 1; pp. 488 - 496
Main Authors Schwende, Francis J., Rykert, Ursula M.
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 19.04.1991
Elsevier
Subjects
Analysis
Biological and medical sciences
Chromatography, High Pressure Liquid - instrumentation
Chromatography, High Pressure Liquid - methods
Fluorescence
General pharmacology
Humans
Medical sciences
Pharmacology. Drug treatments
Phenalenes
Polycyclic Compounds - blood
Polycyclic Compounds - urine
Assay
Human
Urine
Biological fluid
Fluorescence detector
Investigation method
Psychotropic
Dopamine agonist
HPLC chromatography
Blood
Blood plasma
Online AccessGet full text

Cover

More Information
Summary:Alentamol hydrobromide, (+)-2-(dipropylamino)-2,3-dihydro-1H-phenalen-5-ol monohydrobromide, is a selective dopamine agonist currently being investigated for the treatment of schizophrenia. This paper describes a reversed-phase high-performance liquid chromatographic-based method for the quantification of alentamol in blood plasma and urine. The method utilizes solid-phase extraction with carboxylic acid-derivatized silica columns. A limit of quantitation of 0.1 ng/ml in plasma was achieved by virtue of selective extraction and fluorescence detection. Example chromatograms of plasma and urine specimens from clinical trials demonstrate the utility of the method.
ISSN:0378-4347
DOI:10.1016/0378-4347(91)80415-9